Is GNVC a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

345 people get GNVC articles and Market Currents by email alert.

Get email alerts on GNVC »

HEADLINES:

GenVec CEO Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 22
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results

PR Newswire (Mar 22, 2013)
GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013

PR Newswire (Mar 15, 2013)
GenVec to Present at 25th Annual ROTH Conference

PR Newswire (Mar 12, 2013)
3 Small-Cap Biotechs With Zero Debt And Sustainable Revenue
Matt Schilling • Thu, Jan 31 • 3 Comments
Gene Therapy: Which Companies To Invest In?
Dutch Trader • Mon, Jan 28 • 10 Comments
Oncolytics Biotech: What Is All The Excitement About?
C.R. Jackson • Tue, Dec 18, 2012 • 2 Comments
2 Highly Speculative Biotech Stocks Worth A Look In The Wake Of Recent Developments
Matt Schilling • Tue, Dec 18, 2012 • 7 Comments
Single Administration of GenVec's Vaccine Provides Protective Immunity Against HSV in Pre-clinical Animal Models

PR Newswire (Dec 17, 2012)
Promising Data Presented on GenVec Malaria Program

PR Newswire (Nov 14, 2012)
GenVec's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
GenVec Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 9, 2012)
GenVec To Release Third Quarter 2012 Financial Results And Conduct A Conference Call On November 9, 2012

PR Newswire (Nov 2, 2012)
GenVec Enters Into $3.5 Million Contract With Naval Medical Research Center To Advance Malaria Program

PR Newswire (Oct 2, 2012)
Promising Data Presented on GenVec RSV Program

PR Newswire (Oct 1, 2012)
GenVec Announces Reduction in Workforce

PR Newswire (Sep 25, 2012)
GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 9, 2012
GenVec Reports Second Quarter 2012 Financial Results

PR Newswire (Aug 9, 2012)
GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012

PR Newswire (Aug 2, 2012)
5 Pharma Stocks To Buy Along With Sanofi
ValueMax • Mon, Jun 18, 2012 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

GenVec's Pancreatic Cancer Therapy Crashes
Derek Lowe • Tue, Mar 30, 2010 • 2 Comments
GenVec, Inc.: The Biggest Little Biotech
Beta Delta • Fri, Jan 18, 2008 • 9 Comments
Keep Your Eye on GenVec - But Your Money Elsewhere
Rocco Fenton • Fri, Nov 16, 2007 • 2 Comments

3 Small-Cap Biotechs With Zero Debt And Sustainable Revenue
Matt Schilling • Thu, Jan 31 • 3 Comments
Gene Therapy: Which Companies To Invest In?
Dutch Trader • Mon, Jan 28 • 10 Comments
Oncolytics Biotech: What Is All The Excitement About?
C.R. Jackson • Tue, Dec 18, 2012 • 2 Comments
2 Highly Speculative Biotech Stocks Worth A Look In The Wake Of Recent Developments
Matt Schilling • Tue, Dec 18, 2012 • 7 Comments
5 Pharma Stocks To Buy Along With Sanofi
ValueMax • Mon, Jun 18, 2012 • 1 Comment
Life Sciences Companies Raise Record Amounts of Capital
The Burrill Report • Fri, Dec 31, 2010
Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer
Michael Becker • Tue, Oct 26, 2010 • 7 Comments
Competitive Technologies: Short Squeeze Coming or Another Leg Down?
David Greene • Wed, Aug 25, 2010 • 29 Comments
Stocks Claw Back to End Day Lower, Week Higher
Midnight Trader • Fri, Aug 6, 2010 • 3 Comments
Curis Tumbles on Failure of Cancer Drug Trial: Biotech's Latest Mishaps
The Burrill Report • Sun, Jun 20, 2010
Biotech Deal Activity Takes a Breather
The Burrill Report • Sun, Apr 4, 2010
Antisoma Tumbles After Halting Cancer Trial: Biotech's Latest Mishaps
The Burrill Report • Sun, Apr 4, 2010 • 2 Comments
GenVec Slides on Discontinuation of Pancreatic Cancer Drug Trial
The Burrill Report • Sun, Apr 4, 2010 • 1 Comment
A Major Setback for GenVec
Zacks Investment Research • Tue, Mar 30, 2010
GenVec Is Not Just a One Trick Pony
David Greene • Mon, Mar 15, 2010 • 22 Comments
The Case for Registered Direct Offerings
Kevin Pollack • Sun, Feb 14, 2010 • 4 Comments
More Biotech Volatility: Celsius Holdings, Genvec
VFC's Stock House • Thu, Jan 28, 2010 • 3 Comments
2009's Top Sector for Venture Investment: Biotech
The Burrill Report • Mon, Jan 25, 2010 • 1 Comment
Closing Update for Thursday, Sept. 24: Nasdaq, Oil Lead the Decline
Midnight Trader • Thu, Sep 24, 2009 • 1 Comment
Readers Ask: Antares, GenVec, Xoma,
VFC's Stock House • Sun, Sep 13, 2009 • 17 Comments

GenVec CEO Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Mar 22
GenVec's CEO Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Nov 9, 2012
GenVec's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Aug 9, 2012
GenVec, Inc. Q2 2008 Earnings Call Transcript
Fri, Aug 8, 2008
GenVec, Inc. Q1 2008 Earnings Call Transcript
Fri, May 9, 2008
GenVec Inc. Q4 2007 Earnings Call Transcript
Fri, Mar 14, 2008
GenVec Q3 2007 Earnings Call Transcript
Wed, Nov 7, 2007

GenVec Reports Fourth Quarter And 2012 Year-End Financial Results

PR Newswire (Mar 22, 2013)
GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013

PR Newswire (Mar 15, 2013)
GenVec to Present at 25th Annual ROTH Conference

PR Newswire (Mar 12, 2013)
Single Administration of GenVec's Vaccine Provides Protective Immunity Against HSV in Pre-clinical Animal Models

PR Newswire (Dec 17, 2012)
Promising Data Presented on GenVec Malaria Program

PR Newswire (Nov 14, 2012)
GenVec Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 9, 2012)
GenVec To Release Third Quarter 2012 Financial Results And Conduct A Conference Call On November 9, 2012

PR Newswire (Nov 2, 2012)
GenVec Enters Into $3.5 Million Contract With Naval Medical Research Center To Advance Malaria Program

PR Newswire (Oct 2, 2012)
Promising Data Presented on GenVec RSV Program

PR Newswire (Oct 1, 2012)
GenVec Announces Reduction in Workforce

PR Newswire (Sep 25, 2012)
GenVec Reports Second Quarter 2012 Financial Results

PR Newswire (Aug 9, 2012)
GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012

PR Newswire (Aug 2, 2012)
Movers & Shakers: Thursday’s biggest gaining and declining stocks

at MarketWatch.com (Jun 7, 2012)
GenVec Announces Conditional Approval of FMD Vaccine for Cattle

PR Newswire (Jun 7, 2012)
GenVec Reports Inducement Award

PR Newswire (May 25, 2012)
GenVec Appoints Cynthia Collins as President and CEO

PR Newswire (May 21, 2012)
GenVec Reports First Quarter 2012 Financial Results

PR Newswire (May 10, 2012)
GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012

PR Newswire (May 3, 2012)
GenVec Awarded Grant For RSV Vaccine Program

PR Newswire (May 3, 2012)
GenVec Announces Research on Improved Vaccine Vectors

PR Newswire (Apr 6, 2012)

GNVC vs. ETF Alternatives

Company Description

GenVec, Inc. (GenVec, we, our, or the Company) is a clinical stage biopharmaceutical company developing novel, gene-based therapeutic drugs and vaccines. Our lead therapeutic product candidate, TNFeradeTM biologic (TNFerade), is being developed for use in the treatment of cancer. TNFerade is... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 2:25 PM GenVec (GNVC -33%) gets slammed today after its FQ4 missed hard on the revenue side. Sales were down 56% year over year, impacted by a decline in revenue from its hearing loss and balance disorders, HIV, and foot and mouth disease programs. Comment! [Healthcare, Earnings, On the Move]
Monday, May 13, 12:50 PM Midday top 10 gainers: PNTR +65%. TGX +36%. SCTY +33%. CNIT +28%. SUTR +20%. UNIS +19%. ALIM +19%. LEDS +19%. NOAH +17%. HTCH +17%.
Midday top 10 losers: GNVC -34%. ATEA -18%. SBLK -18%. RCON -15%. EOX -8%. DRWI -8%. PLG -8%. MRIN -8%. JOSB -7%. CIMT -7%. Comment! [On the Move]
Thursday, April 11, 12:49 PM Midday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%. Comment! [On the Move]
Friday, March 22, 8:12 AM GenVec (GNVC): Q4 EPS of -$0.24 beats by $0.03. Revenue of $1.5M misses by $2.2M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, December 17, 2012, 12:45 PM Shares of biopharmaceutical developer GenVec (GNVC +37%) surge after the company reported earlier that a single dose of its genetic vaccine showed it was effective against Herpes Simplex Virus or HSV2 in two industry-accepted HSV disease models. The company added that immunization was also shown to reduce viral shedding and the recurrence and severity of lesions. Comment! [Healthcare, On the Move]
Monday, December 17, 2012, 12:45 PM Midday top 10 gainers: GNVC +37%. CBOU +30%. HRT +16%. CEDC +15%. OCZ +13%. CPWR +13%. ONCY +13%. JVA +12%. VELT +12%. HTCH +12%.
Midday top 10 Losers: SCL -48%. GYRO -31%. END -20%. OPXA -13%. CLWR -12%. XUE -12%. SSE -11%. ALIM -11%. RVM -11%. NBG -9%. 1 Comment [On the Move]
Monday, October 1, 2012, 1:31 PM Shares of biopharmaceutical developer GenVec (GNVC +4.4%) jump after releasing positive data on one of its RSV vaccine programs at a conference over the weekend. The company says data on its vaccine candidate showed it to be highly immunogenic and avoids the problems of vector specific immunity that has hampered other similar vectored vaccines. Comment! [Healthcare, On the Move]
Thursday, June 7, 2012, 8:33 AM GenVec (GNVC) surging 19% after the USDA's Animal & Plant Health Inspection Service grants a conditional license for GenVec's vaccine for foot-and-mouth disease for use in cattle. GenVec also licenses the rights to develop and commercialize the technology to Sanofi's (SNY) Merial unit. (PR) 2 Comments [On the Move, Healthcare]
Tuesday, March 30, 2010, 10:39 AM GenVec (GNVC) tumbles 71.9% after it discontinues a trial for its lead gene therapy drug for pancreatic cancer. Interim results showed it was unlikely to become effective. Comment!
Friday, March 19, 2010, 9:00 AM Premarket gainers: LYG +10%. LGF +8%. CRBC +8%. GNVC +4%. RBS +4%. BBY +4%. AIB +4%.
Losers: PALM -17%. SPWRA -10%. SB -7%. GNBT -7%. HT -4%. GSL -4%. 1 Comment
Monday, March 8, 2010, 9:00 AM Premarket gainers: XRTX +17%. CTIC +16%. CHGS +11%. SEED +11%. ANO +8%. MSN +8%. CNAM +7%. EBIX +6%. GMO +5%. AIG +4%. RFMD +4%. MET +4%. GNVC +4%. IMAX +4%.
Losers: LXRX -10%. TTM -7%. IRE -6%. SSTI -6%. YRCW -4%. AIB -4%. PEIX -4%. Comment!
Friday, March 5, 2010, 9:00 AM Premarket gainers: ITMN +81%. AIB +13%. TIVO +8%. IRE +6%. CPBY +6%. GNVC +4%. AGT +4%.
Losers: GPRE -6%. CNXT -6%. NG -5%. OSG -4%. Comment!
Wednesday, March 3, 2010, 9:10 AM Premarket gainers: SWWC +52%. NOVL +28%. LSCC +12%. DAN +6%. HOV +5%. PUK +5%. CLDX +4%. ELN +4%. GNVC +4%. BCS +4%. JOYG +4%.
Losers: MDVN -68%. VISN -28%. CMED -7%. CPNO -5%. PAY -5%. NFLX -5%. Comment!
Tuesday, February 16, 2010, 9:00 AM Premarket gainers: TRA +22%. DSCO +19%. CPSL +16%. NIHD +12%. BCS +11%. APWR +8%. NVMI +6%. GNVC +5%. GNRC +4%. SNV +4%. UBS +4%. HL +4%. IOC +4%. ARTG +4%.
Losers: RIGL -8%. OTE -8%. PMI -5%. NBG -5%. CTIC -5%. STEC -4%. Comment!
Wednesday, January 27, 2010, 9:10 AM Premarket gainers: MNI +19%. ME +18%. SANM +16%. PXP +9%. BRK +8%. ROK +7%. KT +7%. GILD +6%. ALTR +5%. TEL +5%. GNVC +5%. F +4%. APC +4%. AAI +4%. UAUA +4%.
Premarket losers: TSFG -18%. HERO -11%. FSIN -5%. CAT -5%. CX -4%. Comment!
Tuesday, January 26, 2010, 9:00 AM Premarket gainers: VMW +16%. AMLN +16%. ALKS +14%. SHW +6%. TLAB +6%. ZION +5%. NVO +4%. SIRI +4%. BHI +4%. TRV +4%.
Losers: WFT -8%. FUN -6%. X -5%. GNVC -4%. ARCC -4%. Comment!

freefdawatchlist
Earnings b4 market open: $ACCO $ALT $AG, $ADY $MT $ATPG $BIOD $CSIQ $DYN $GNVC $INO, $NHI $PDCE $RGDX $SOMX $VITC $SNE $SLF $TGX $VITC $WIN
5/10/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Guy T
GNVC only "BAD " pick in my portfolio. Stock MUST get to $1.00 soon or get delisted....Bought at $ 0.51 ....
6/21/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Rafie Trading
AONEQ.PK, GNVC, NBG, BRCD...could all move nicely today towards 14.45, 1.00 , 4.26. and 6.78 respectively
4/12/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Rafie Trading
GNVC might bounce back
4/5/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

OTCShowcase
Daytrade: GNVC. Long term: investing Cellceutix real heavy. I'm loving them as a long-term play from everything I see.
3/30/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ramram77
Whatever thoughts made me sell GNVC last week.. I say thank you
3/29/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tahoe00
GNVC.trading at .76, expect a class action lawsuit soon.They raised a secondary offering at 1.80 ,60 days ago,then shut down a phase 3 trial
3/29/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tahoe00
GNVC $2.74 up 5%, life extention for patients with pancreatic cancer. Midterm phase 3 results coming in 4 weeks. Goal is $3.75. Buy and hold
3/4/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

AlphaLoboTrading
GNVC -1.83- coming off support (daily,weekly) looking for stock to continue higher on momentum and retest 3.00
2/11/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
GNVC -- 13 new highs in 20 sessions
1/25/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

GNVC GenVec, Inc.

GNVC

GenVec, Inc.